Abstract:Objective To analyze the clinical effect of early clearance of bloody cerebrospinal fluid (CSF) in the treatment of traumatic brain injury.Methods A total of 82 patients with traumatic brain injury admitted to Wuxi Fifth People's Hospital from July 2023 to January 2025 were selected and divided into a group undergoing conventional treatment (control group, n = 41) and the other with early clearance of bloody CSF (experimental group, n = 41) by stratified random sampling. The clinical efficacy, intracranial pressure, serum indicators [lactic acid (Lac), cortisol (Cor), norepinephrine (NE), C-reactive protein (CRP) ], neurological function [Modified Rankin Scale (MRS) and National Institutes of Health Stroke Scale (NIHSS) scores], functional prognosis [Glasgow Outcome Scale (GOS) and Disability Rating Scale (DRS) scores], and immune function (CD4+, CD8+, CD4+/CD8+) were compared between the two groups.Results The overall effective rate in the experimental group was higher than that in the control group (P < 0.05). On postoperative day 7, the intracranial pressure in the experimental group was lower than that in the control group (P < 0.05). At 2 weeks postoperatively, the Lac level in the experimental group was lower than that in the control group (P < 0.05). At 4 weeks postoperatively, the levels of Cor, NE, and CRP in the experimental group were all lower than those in the control group (P < 0.05). At 4 weeks after surgery, the MRS and NIHSS scores in the experimental group were lower than those in the control group (P < 0.05). The GOS scores in the experimental group were higher than those in the control group (P < 0.05). The DRS scores at 4 weeks postoperatively were lower in the experimental group than in the control group (P < 0.05). In addition, the levels of CD4+, CD8+, and CD4+/CD8+ at 4 weeks postoperatively were significantly higher in the experimental group compared to the control group (P < 0.05).Conclusion Early clearance of bloody CSF has a significant therapeutic effect in patients with traumatic brain injury, effectively reducing intracranial pressure, improving serum biomarkers and neurological function, and enhancing both functional outcomes and immune status.